PhRMA submits comments to OSTP on enhancing clinical trial diversity
The White House ’s Office of Science and Technology Policy (OSTP) recently solicited stakeholder feedback on the clinical research infrastructure for emergency clinical trials, for which PhRMA submitted comments. PhRMA shares OSTP’s recognition of the importance of having a clinical trial infrastructure that su pports sites that are ready to respond to emergency situations like COVID-19. We also agree that one goal of such an infrastructure should be to support the expansion of clinical research into underserved communities by increasing diversity among both trial participants and clinical trial investigat ors.
Source: The Catalyst - Category: Pharmaceuticals Authors: Maria Apostolaros Tags: Research and Development Clinical Trials Coronavirus Source Type: news
More News: Clinical Trials | Coronavirus | COVID-19 | Emergency Medicine | Pharmaceuticals | Science